{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:04:22Z","timestamp":1783904662726,"version":"3.55.0"},"reference-count":27,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_raon-2019-0044_s_005\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The Hybrid Capture 2 (HC2) High-Risk HPV DNA assay serves as a triage test in the Slovenian national cervical cancer screening programme ZORA. To improve the limited analytical accuracy of HC2 test results near the cut-off value (1.0 relative light units\/cut-off (RLU\/CO)), we follow an internal protocol of repeating the test on all samples with borderline results within the 0.7-2.0 RLU\/CO interval. The aim of the study was (i) to determine the clinical relevance of HC2 test results within three different \u201cgrey zones\u201d for samples stored in Specimen Transport Medium (STM) and (ii) to determine whether the current algorithm of retesting \u201cgrey zone\u201d STM specimens with the HC2 assay is clinically relevant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_raon-2019-0044_s_006\">\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>The study included 594 women between 20 and 65 years of age. All participating women were referred for colposcopy, and in cases of abnormal results, biopsy was performed. We assessed the distribution of HC2 test results and the corresponding proportion of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) lesions in three different \u201cgrey zones\u201d (1.0\u20132.5, 0.4\u20134.0 and 0.7\u20132.0 RLU\/CO), retested specimens with results within a 0.4\u20134.0 RLU\/CO interval and calculated the sensitivity and specificity for HC2 at different RLU\/CO values.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_raon-2019-0044_s_007\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The proportion of specimens within 1.0\u20132.5, 0.4\u20134.0 and 0.7\u20132.0 RLU\/CO intervals was 3.9%, 10.8% and 4.5%, respectively. The proportion of CIN2+ lesions within these \u201cgrey zones\u201d was 2.5%, 5.6% and 1.2%, respectively. Retesting the samples did not detect any additional CIN2+ cases. Within the 1.0\u20132.5 RLU\/CO interval, the sensitivity decreased from 93.8% to 91.4%, while the specificity increased from 63.3% to 67.5%; for the 0.4\u20134.0 RLU\/CO interval, the sensitivity decreased from 95.1% to 89.5%, while the specificity increased from 56.8% to 69.4%; and for the 0.7\u20132.0 RLU\/CO interval, the sensitivity remained nearly constant (94.4\n                      <jats:italic>vs<\/jats:italic>\n                      . 93.2%), while the specificity increased from 60.6% to 66.4%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_raon-2019-0044_s_008\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results show that retesting STM samples within the \u201cgrey zones\u201d is not necessary. Retesting samples in the negative \u201cgrey zone\u201d does not increase sensitivity, and retesting in the positive \u201cgrey zone\u201d is not followed by a less intensive management of women, since these women are recalled regardless of the results of the retest. Furthermore, the majority of samples retain the original HC2 results after retest, and the number of CIN2+ lesions among women with \u201cgrey zone\u201d HC2 results is low.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/raon-2019-0044","type":"journal-article","created":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T18:20:38Z","timestamp":1569435638000},"page":"316-322","source":"Crossref","is-referenced-by-count":2,"title":["Clinical relevance of the borderline results of the Hybrid Capture 2 High-Risk HPV DNA assay with cervical samples collected in Specimen Transport Medium"],"prefix":"10.2478","volume":"53","author":[{"given":"Jerneja","family":"Varl","sequence":"first","affiliation":[{"name":"Department of Experimental Oncology, Institute of Oncology Ljubljana , Ljubljana , Slovenia"},{"name":"University of Ljubljana, Faculty of Medicine , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urska","family":"Ivanus","sequence":"additional","affiliation":[{"name":"ZORA National Cervical Cancer Screening Programme, Epidemiology and Cancer Registry, Institute of Oncology Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziva Pohar","family":"Marinsek","sequence":"additional","affiliation":[{"name":"Department of Cytopathology, Institute of Oncology Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tine","family":"Jerman","sequence":"additional","affiliation":[{"name":"ZORA National Cervical Cancer Screening Programme, Epidemiology and Cancer Registry, Institute of Oncology Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja Ostrbenk","family":"Valencak","sequence":"additional","affiliation":[{"name":"Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Poljak","sequence":"additional","affiliation":[{"name":"Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika Kloboves","family":"Prevodnik","sequence":"additional","affiliation":[{"name":"Department of Cytopathology, Institute of Oncology Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2019,9,24]]},"reference":[{"key":"2026071215065383677_j_raon-2019-0044_ref_001","unstructured":"Ursi\u010d Vr\u0161\u010daj M, Rakar S, Mo\u017eina A, Kobal B, Taka\u010d I, Deisinger I, et al. [Guidelines for management of women with cervical precancerous lesions]. [Slovenian]. In: Ursic-Vrscaj M, editor. Ljubljana: Institute of Oncology Ljubljana; 2011."},{"key":"2026071215065383677_j_raon-2019-0044_ref_002","unstructured":"Hybrid Capture 2 (hc2) High Risk HPV DNA test kit [package insert]. Gaithersburg, MD: Digene; 2004."},{"key":"2026071215065383677_j_raon-2019-0044_ref_003","doi-asserted-by":"crossref","unstructured":"Castle PE, Lorincz AT, Mielzynska-Lohnas I, Scott DR, Glass AG, Sherman ME, et al. Results of human papillomavirus DNA testing with the Hybrid Capture 2 assay are reproducible. J Clin Microbiol 2002; 40: 1088-90. doi: 10.1158\/1055-9965.EPI-07-2904","DOI":"10.1128\/JCM.40.3.1088-1090.2002"},{"key":"2026071215065383677_j_raon-2019-0044_ref_004","doi-asserted-by":"crossref","unstructured":"Castle PE, Wheeler CM, Solomon D, Schiffman M, Peyton CL; ALTS Group. Interlaboratory reliability of Hybrid Capture 2. Am J Clin Pathol 2004; 122: 238-45. doi: 10.1158\/1055-9965.EPI-07-2904","DOI":"10.1309\/BA43HMCAJ26VWQH3"},{"key":"2026071215065383677_j_raon-2019-0044_ref_005","doi-asserted-by":"crossref","unstructured":"Carozzi FM, Del Mistro A, Confortini M, Sani C, Puliti D, Trevisan R, et al. Reproducibility of HPV DNA testing by Hybrid Capture 2 in a screening setting. Am J Clin Pathol 2005; 124: 716-21. doi: 10.1309\/84E5WHJQHK83BGQD","DOI":"10.1309\/84E5WHJQHK83BGQD"},{"key":"2026071215065383677_j_raon-2019-0044_ref_006","doi-asserted-by":"crossref","unstructured":"Seme K, Fujs K, Kocjan BJ, Poljak M. Resolving repeatedly borderline results of Hybrid Capture 2 HPV DNA Test using polymerase chain reaction and genotyping. J Virol Methods 2006; 134: 252-6. doi: 10.1016\/j. jviromet.2005.12.004","DOI":"10.1016\/j.jviromet.2005.12.004"},{"key":"2026071215065383677_j_raon-2019-0044_ref_007","unstructured":"Origoni M, Carminati G, Sideri M, Clementi M, Rolla S, Candiani M. \u201cLow-grade positivity\u201d of HPV viral load after atypical squamous cells of undetermined significance (ASC-US) cytology identifies women at low-risk for cervical intraepithelial neoplasia grade 2 and 3. Eur J Gynaecol Oncol 2012; 33: 261-4. PMID: 22873095"},{"key":"2026071215065383677_j_raon-2019-0044_ref_008","doi-asserted-by":"crossref","unstructured":"de Cremoux P, Coste J, Sastre-Garau X, Thioux M, Bouillac C, Labbe S, et al. Efficiency of the Hybrid Capture 2 HPV DNA test in cervical cancer screening. A study by the French Society of Clinical Cytology. Am J Clin Pathol 2003; 120: 492-9. doi: 10.1309\/XFUC-PP6M-5XUA-94B8","DOI":"10.1309\/XFUCPP6M5XUA94B8"},{"key":"2026071215065383677_j_raon-2019-0044_ref_009","doi-asserted-by":"crossref","unstructured":"Muldrew KL, Beqaj SH, Han J, Lum SH, Clinard V, Schultenover SJ, et al. Evaluation of a Digene-recommended algorithm for human papillomavirus low-positive results present in a \u201cretest zone\u201d. Am J Clin Pathol 2007; 127: 97-102. doi: 10.1309\/4WCPTUV506HLP06P","DOI":"10.1309\/4WCPTUV506HLP06P"},{"key":"2026071215065383677_j_raon-2019-0044_ref_010","doi-asserted-by":"crossref","unstructured":"Rao A, Sandri MT, Sideri M, Young S, Sharma A, Behrens C. Comparison of hybrid capture 2 High-Risk HPV results in the low positive range with cobas\u00ae HPV Test results from the ATHENA study. J Clin Virol 2013; 58: 161-7. doi: 10.1016\/j.jcv.2013.06.041","DOI":"10.1016\/j.jcv.2013.06.041"},{"key":"2026071215065383677_j_raon-2019-0044_ref_011","doi-asserted-by":"crossref","unstructured":"Knoepp SM, Kuebler DL, Wilbur DC. Resolution of equivocal results with the Hybrid Capture II high-risk HPV DNA test: a cytologic\/histologic review of 191 cases. Diagn Mol Pathol 2007; 16: 125-9. doi: 10.1097\/ PDM.0b013e31805c99ae","DOI":"10.1097\/PDM.0b013e31805c99ae"},{"key":"2026071215065383677_j_raon-2019-0044_ref_012","doi-asserted-by":"crossref","unstructured":"Knoepp SM, Kuebler DL, Wilbur DC. Correlation between hybrid capture II high-risk human papillomavirus DNA test chemiluminescence intensity from cervical samples with follow-up histologic results: a cytologic\/ histologic review of 367 cases. Cancer Cytopathol 2010; 118: 209-17. doi: 10.1002\/cncy.20093","DOI":"10.1002\/cncy.20093"},{"key":"2026071215065383677_j_raon-2019-0044_ref_013","doi-asserted-by":"crossref","unstructured":"LaMere BJ, Castle PE, Fetterman B, Poitras N, Stanley M, Shieh J, et al. A study of borderline positive Hybrid Capture 2 tests in the Kaiser Permanente Northern California cervical screening program: evidence against retesting. J Virol Methods 2013; 189: 77-9. doi: 10.1016\/j.jviromet.2013.01.011","DOI":"10.1016\/j.jviromet.2013.01.011"},{"key":"2026071215065383677_j_raon-2019-0044_ref_014","doi-asserted-by":"crossref","unstructured":"Elkins CT, de Vries CE, Stephens J, Suarez AA. Hybrid capture 2 test results after an initial equivocal RLU\/CO value are dependent on age. Am J Clin Pathol 2013; 139: 605-10. doi: 10.1309\/AJCPARHTB40DTVFV","DOI":"10.1309\/AJCPARHTB40DTVFV"},{"key":"2026071215065383677_j_raon-2019-0044_ref_015","unstructured":"Ramirez-Hidalgo A, Musset-Biarnes M, Vilamala-Muns M, Laso-Perez E, Serrano-Munne L, Alameda-Quitllet F. Hybrid capture 2 high-risk human papillomavirus test: should \u201cgrey zone\u201d results justify repeating the test? Anal Quant Cytopathol Histpathol 2013; 35: 152-6. PMID: 24344502"},{"key":"2026071215065383677_j_raon-2019-0044_ref_016","doi-asserted-by":"crossref","unstructured":"de Vries CE, Shen R, Stephens J, Suarez AA. Equivocal and weakly positive hybrid capture 2 test in women aged 50 and older. Diagn Cytopathol 2012; 40: 708-12. doi: 10.1002\/dc.21710","DOI":"10.1002\/dc.21710"},{"key":"2026071215065383677_j_raon-2019-0044_ref_017","doi-asserted-by":"crossref","unstructured":"Ivanus U, Jerman T, Fokter AR, Takac I, Prevodnik VK, Marcec M, et al. Randomised trial of HPV self-sampling among non-attenders in the Slovenian cervical screening programme ZORA: comparing three different screening approaches. Radiol Oncol 2018; 52: 399-412. doi: 10.2478\/ raon-2018-0036","DOI":"10.2478\/raon-2018-0036"},{"key":"2026071215065383677_j_raon-2019-0044_ref_018","unstructured":"Kurman RJ, Carcangiu ML, Herrington CS, Young RH, editors. WHO classification of tumours of female reproductive organs. 4th edition. Lyon: International Agency for Research on Cancer; 2014."},{"key":"2026071215065383677_j_raon-2019-0044_ref_019","unstructured":"R Core Team. The R Project for Statistical Computing R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing; 2019. [cited 2019 May 15]. Available at: http:\/\/www.R-project.org\/"},{"key":"2026071215065383677_j_raon-2019-0044_ref_020","doi-asserted-by":"crossref","unstructured":"Kotaniemi-Talonen L, Malila N, Nieminen P, Anttila A, Tarkkanen J, Laurila P, et al. Test positivity cutoff level of a high risk human papillomavirus test could be increased in routine cervical cancer screening. Int J Cancer 2008; 123: 2902-6. doi: 10.1002\/ijc.23839.","DOI":"10.1002\/ijc.23839"},{"key":"2026071215065383677_j_raon-2019-0044_ref_021","doi-asserted-by":"crossref","unstructured":"Ronco G, Giorgi-Rossi P, Carozzi F, Dalla Palma P, Del Mistro A, De Marco L, et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol 2006; 7: 547-55. doi: 10.1016\/ S1470-2045(06)70731-8","DOI":"10.1016\/S1470-2045(06)70731-8"},{"key":"2026071215065383677_j_raon-2019-0044_ref_022","doi-asserted-by":"crossref","unstructured":"Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F, et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst 2006; 98: 765-74. doi: 10.1093\/jnci\/djj209","DOI":"10.1093\/jnci\/djj209"},{"key":"2026071215065383677_j_raon-2019-0044_ref_023","doi-asserted-by":"crossref","unstructured":"Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 2008; 100: 492-501. doi: 10.1093\/jnci\/djn065","DOI":"10.1093\/jnci\/djn065"},{"key":"2026071215065383677_j_raon-2019-0044_ref_024","doi-asserted-by":"crossref","unstructured":"Sargent A, Bailey A, Turner A, Almonte M, Gilham C, Baysson H, et al. Optimal threshold for a positive hybrid capture 2 test for detection of human papillomavirus: data from the ARTISTIC trial. J Clin Microbiol 2010; 48: 554-8. doi: 10.1128\/JCM.00896-09","DOI":"10.1128\/JCM.00896-09"},{"key":"2026071215065383677_j_raon-2019-0044_ref_025","doi-asserted-by":"crossref","unstructured":"Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 2001; 84: 1616-23. doi: 10.1054\/bjoc.2001.1845","DOI":"10.1054\/bjoc.2001.1845"},{"key":"2026071215065383677_j_raon-2019-0044_ref_026","doi-asserted-by":"crossref","unstructured":"Rijkaart DC, Coupe VM, van Kemenade FJ, Heideman DA, Hesselink AT, Verweij W, et al. Comparison of Hybrid capture 2 testing at different thresholds with cytology as primary cervical screening test. Br J Cancer 2010; 103: 939-46. doi: 10.1038\/sj.bjc.6605869","DOI":"10.1038\/sj.bjc.6605869"},{"key":"2026071215065383677_j_raon-2019-0044_ref_027","doi-asserted-by":"crossref","unstructured":"Rebolj M, Bonde J, Njor SH, Lynge E. Human papillomavirus testing in primary cervical screening and the cut-off level for hybrid capture 2 tests: systematic review. BMJ 2011; 23: 342. doi: 10.1136\/bmj.d2757","DOI":"10.1136\/bmj.d2757"}],"container-title":["Radiology and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/content.sciendo.com\/view\/journals\/raon\/53\/3\/article-p316.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/raon-2019-0044","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:04:44Z","timestamp":1783901084000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/raon-2019-0044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,1]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,9,24]]},"published-print":{"date-parts":[[2019,9,24]]}},"alternative-id":["10.2478\/raon-2019-0044"],"URL":"https:\/\/doi.org\/10.2478\/raon-2019-0044","relation":{},"ISSN":["1581-3207"],"issn-type":[{"value":"1581-3207","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,1]]}}}